Drug intelligence / Profile preview

zibotentan + placebo

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

Zibotentan + placebo refers to a clinical trial regimen where zibotentan (an endothelin A receptor antagonist) is being compared to placebo. Zibotentan is a potent and specific orally available endothelin A (ETA) receptor antagonist with no measurable affinity for endothelin B receptor. It inhibits endothelin-mediated mechanisms that promote tumor cell proliferation. This combination has been studied in various clinical trials for conditions including prostate cancer, microvascular angina, and chronic kidney disease.

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on zibotentan + placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zibotentan + placebo.

Explore the full profile